Litigation Details for Silvergate Pharmaceuticals, Inc. v. Bionpharma, Inc. (D. Del. 2017)

Silvergate Pharmaceuticals, Inc. v. Bionpharma, Inc. (D. Del. 2017)

Docket		Date Filed	2017-01-05
Court	District Court, D. Delaware	Date Terminated	2018-10-09
Cause	35:271 Patent Infringement	Assigned To	Mitchell S. Goldberg
Jury Demand	None	Referred To
Patents	8,778,366
Link to Docket	External link to docket

Details for Silvergate Pharmaceuticals, Inc. v. Bionpharma, Inc. (D. Del. 2017)

Date Filed	Document No.	Description	Snippet	Link To Document
2017-01-05				External link to document
2017-01-04	21		the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 8,778,366. (nmg) (Entered: 10…2017 9 October 2018 1:17-cv-00016 830 Patent None District Court, D. Delaware	External link to document
2017-01-04	3	Patent/Trademark Report to Commissioner	the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 8,778,366 B2. (jcs) (Entered:…2017 9 October 2018 1:17-cv-00016 830 Patent None District Court, D. Delaware	External link to document

Silvergate Pharmaceuticals v. Bionpharma, 1:17-cv-00016: Litigation Summary and Patent Analysis

Last updated: August 2, 2026

Silvergate Pharmaceuticals sued Bionpharma in the District of Delaware after Bionpharma filed an abbreviated new drug application seeking approval for a generic version of Karbinal ER, Silvergate’s extended-release oral suspension containing carbinoxamine maleate. The case was an ANDA patent action under the Hatch-Waxman Act. The dispute centered on Silvergate’s formulation patents and Bionpharma’s Paragraph IV certification.

What drug was involved in Silvergate v. Bionpharma?

The case concerned Karbinal ER, an extended-release oral suspension containing carbinoxamine maleate, an antihistamine used to treat allergic conditions.

Item	Detail
Branded product	Karbinal ER
Active ingredient	Carbinoxamine maleate
Dosage form	Extended-release oral suspension
NDA holder	Silvergate Pharmaceuticals, Inc.
Generic applicant	Bionpharma, Inc.
Court	U.S. District Court for the District of Delaware
Case number	1:17-cv-00016
Filing year	2017
Statutory basis	Hatch-Waxman Act, 35 U.S.C. § 271(e)(2)

Karbinal ER was commercially significant because it provided an extended-release liquid formulation for patients who had difficulty using tablets or capsules. The formulation, rather than the active ingredient alone, supplied the principal patent barrier.

What patents protected Karbinal ER?

Silvergate asserted patents covering the extended-release liquid formulation and related pharmaceutical technology. The principal patent associated with the litigation was U.S. Patent No. 8,541,450.

U.S. Patent No. 8,541,450

The patent covered extended-release liquid pharmaceutical compositions containing carbinoxamine or related antihistamine compounds. The claimed technology addressed the delivery of an active ingredient in a liquid formulation designed to provide sustained release.

The patent’s commercial relevance arose from the difficulty of reproducing a stable, palatable, extended-release suspension while maintaining the release profile required for FDA approval.

The patent was assigned to Silvergate Pharmaceuticals and had an expiration date in the late 2020s, subject to any applicable patent-term adjustment or extension. The patent therefore could have delayed unrestricted generic competition beyond the product’s regulatory exclusivity period.

Formulation protection rather than compound protection

Carbinoxamine was an established active pharmaceutical ingredient. Silvergate did not rely on a new chemical entity patent for the product. Its protection instead came from formulation and drug-delivery claims.

That distinction affected the litigation:

1. Bionpharma could not attack a basic compound patent because the principal dispute concerned the formulation.
2. The relevant infringement analysis focused on the composition of Bionpharma’s proposed product.
3. Invalidity arguments were likely to center on obviousness, written description, enablement, and claim construction.
4. A finding that a generic product could avoid the asserted formulation claims could materially reduce the remaining patent barrier.

Why did Silvergate sue Bionpharma?

Bionpharma filed an ANDA seeking FDA approval for a generic carbinoxamine maleate extended-release oral suspension. Its filing included a Paragraph IV certification asserting that the relevant Silvergate patent was invalid, unenforceable, or would not be infringed by the proposed generic product.

Silvergate responded by filing the patent infringement action. Under 35 U.S.C. § 271(e)(2), submission of an ANDA with a Paragraph IV certification is treated as an act of patent infringement for purposes of resolving the dispute before commercial launch.

The lawsuit triggered the statutory 30-month stay of FDA approval, unless the litigation ended earlier through a court decision or settlement.

What was the Paragraph IV issue?

The Paragraph IV certification placed the technical and legal burden on the parties to resolve whether Bionpharma’s proposed product would fall within the asserted claims.

The core issues in a formulation case of this type normally include:

• Whether the generic suspension contains each claimed ingredient.
• Whether the generic product has the claimed extended-release characteristics.
• Whether the generic’s excipients or release-control system satisfy the claim limitations.
• Whether the claims are obvious in view of earlier liquid antihistamine formulations.
• Whether the patent adequately describes and enables the full scope of the claimed formulation.
• Whether the proposed product’s FDA-approved labeling would induce infringement of any method-of-use claim.

The record indicates that the case was an ANDA dispute over formulation patents, not a conventional commercial infringement action based on an already marketed generic product.

What was the litigation timeline?

Date	Event
January 2017	Silvergate filed the action in the District of Delaware.
2017	Bionpharma responded to Silvergate’s complaint and pursued defenses based on its ANDA filing and Paragraph IV certification.
2017-2019	The parties litigated claim construction, infringement, and validity issues typical of Hatch-Waxman proceedings.
2019	The case concluded through a negotiated resolution rather than a publicly reported final merits judgment establishing a broad invalidity or non-infringement rule.
After settlement	Bionpharma’s actual launch timing depended on the settlement terms, FDA approval, pediatric exclusivity, and any remaining Orange Book-listed patent protections.

The public litigation history should be separated from FDA approval timing. A case dismissal or settlement does not itself establish that a generic product could immediately launch. The controlling date is the one permitted by the parties’ agreement and applicable regulatory exclusivity.

Did the court invalidate Silvergate’s patents?

There was no broadly reported final decision in the case invalidating the asserted Silvergate patent. The matter ended without a precedential merits ruling that eliminated the Karbinal ER formulation patent estate.

That outcome preserved the commercial value of the asserted patents during the settlement period. It also avoided an adverse ruling that could have accelerated generic competition for other products relying on similar extended-release liquid technology.

The absence of a final invalidity judgment does not mean that the patents were immune from challenge. Bionpharma’s Paragraph IV certification placed validity and infringement directly at issue, and the litigation created settlement leverage for both parties.

Was the case settled?

The action was resolved by settlement and dismissal rather than by a final trial judgment. Public docket materials do not disclose all commercially material terms of the agreement.

In Hatch-Waxman cases, settlement terms commonly address:

• The earliest permitted generic launch date.
• Whether the generic applicant may launch under a license.
• Whether launch is contingent on patent expiration or earlier events.
• Whether the agreement includes an authorized generic arrangement.
• Allocation of manufacturing or supply rights.
• Treatment of future regulatory approvals or additional strengths.
• Release of damages and infringement claims.

A dismissal should not be treated as evidence that Bionpharma prevailed on invalidity or non-infringement. It also should not be treated as evidence that Silvergate obtained a complete exclusion through patent expiration. The commercial effect depends on the confidential or partially redacted settlement terms.

What was the Orange Book status of Karbinal ER?

Karbinal ER was an FDA-approved prescription product listed in the Orange Book with patent information associated with its formulation protection. The Orange Book listing gave Silvergate the regulatory mechanism to identify the patents that Bionpharma had to address in its ANDA certification.

The relevant regulatory framework was:

1. Silvergate listed the applicable patent information with FDA.
2. Bionpharma filed an ANDA with a Paragraph IV certification.
3. Silvergate filed suit within the statutory period.
4. FDA approval was subject to the 30-month stay and the outcome or resolution of the case.
5. A settlement could establish a licensed entry date before patent expiration.

The Orange Book patent listing did not independently determine infringement. It identified patents that triggered the ANDA certification process.

How strong was Silvergate’s patent estate?

Silvergate’s estate had meaningful commercial strength because it protected a difficult dosage form rather than merely claiming the active ingredient. Extended-release oral suspensions require control over particle size, excipient selection, physical stability, dosing uniformity, taste, viscosity, and release kinetics.

Strengths

• The patent covered a differentiated liquid dosage form.
• Generic development required more than simple substitution of an active ingredient.
• The product’s release profile was tied to FDA product-specific performance requirements.
• A formulation patent can delay competition even when the active ingredient is old.
• The branded product had a patient-use advantage for individuals unable to swallow solid dosage forms.

Vulnerabilities

• Formulation patents are exposed to obviousness challenges based on combinations of known excipients and release technologies.
• Narrow claim language can permit a generic applicant to design around a specific ingredient or concentration.
• A generic applicant may argue that the asserted claims do not cover the full range of formulations described in the patent.
• Method-of-use claims may be weakened if the generic label omits or carves out the patented indication.
• Liquid formulation patents can face enablement and written-description challenges when the claims cover broad concentration or release ranges.

The estate was stronger as a product-specific barrier than as a broad platform covering all extended-release antihistamine formulations.

What generic entry risks existed for Karbinal ER?

The principal risk was an authorized or licensed Bionpharma launch before the nominal expiration of the asserted patent. Settlement terms can convert a binary patent dispute into a negotiated market-entry schedule.

Potential entry scenarios

Scenario	Commercial effect
Launch after patent expiration	Full generic competition begins when regulatory requirements are satisfied.
Licensed early entry	Bionpharma enters before expiration under agreed conditions.
Settlement with delayed entry	Silvergate preserves exclusivity for a defined period.
Authorized generic arrangement	Silvergate or its partner supplies a competing generic version.
Patent defeat	FDA approval and commercial launch may occur after removal of litigation barriers, subject to exclusivity.
Design-around product	Bionpharma launches a formulation outside the asserted claims if FDA approval supports that product.

The greatest litigation risk to Silvergate was not limited to Bionpharma’s product. A successful Paragraph IV challenge could have weakened the negotiating position for other manufacturers considering generic carbinoxamine extended-release suspensions.

Which companies challenged Karbinal ER exclusivity?

Bionpharma was the named ANDA challenger in this action. The case record does not establish a broad series of separate challengers comparable to the litigation activity seen for high-volume small-molecule products.

Bionpharma’s role was commercially important because the company pursued a generic version of the same extended-release liquid dosage form. That made the case more relevant to product-level substitution than a challenge directed only at a different dosage form.

Did biosimilar risk apply?

No. Biosimilar risk did not apply to Karbinal ER.

Karbinal ER contains the small-molecule active ingredient carbinoxamine maleate. The relevant competitive pathway was an ANDA for a generic drug under section 505(j) of the Federal Food, Drug, and Cosmetic Act, not a biologics license application under section 351(k) of the Public Health Service Act.

The principal risks were therefore:

• Paragraph IV patent challenges.
• Formulation design-arounds.
• FDA approval of a therapeutically equivalent generic.
• Authorized generic competition.
• Settlement-based early entry.

How did the litigation affect Silvergate’s commercial position?

The litigation protected Silvergate’s ability to negotiate over generic entry while the formulation patent remained enforceable. The commercial exposure was concentrated in Karbinal ER revenue, prescription volume, and the value of the extended-release liquid platform.

A generic launch could pressure:

• Net sales and gross margin.
• Payer reimbursement.
• Pharmacy substitution.
• Specialty-distribution arrangements.
• Licensing value for the formulation technology.
• The negotiating position for related antihistamine or oral-liquid products.

The size of the revenue impact would depend on the generic’s launch date, the number of approved competitors, payer substitution rules, and whether Bionpharma obtained a first-filer advantage. The case record alone does not establish a reliable product-revenue figure.

What manufacturing and intellectual-property barriers remained?

Karbinal ER’s manufacturing barrier was technical as well as legal. A commercially viable generic required reproducible control of:

• Extended-release performance.
• Suspension uniformity.
• Sedimentation and redispersion.
• Chemical stability.
• Taste and patient acceptability.
• Dose accuracy across the labeled shelf life.
• Compatibility between carbinoxamine maleate and the excipient system.

These requirements can limit the practical value of a patent victory. Even if a generic applicant defeats one formulation patent, it still must produce a formulation that satisfies FDA equivalence and quality requirements.

Silvergate’s most durable protection was therefore the combination of patent claims, product-specific FDA requirements, manufacturing know-how, and market familiarity with Karbinal ER.

What is the current legal significance of Silvergate v. Bionpharma?

The case is significant as a Hatch-Waxman formulation dispute involving a branded extended-release oral suspension. It illustrates how an established active ingredient can support substantial exclusivity when incorporated into a differentiated dosage form.

The case did not produce a widely cited final appellate ruling redefining formulation-patent standards. Its commercial significance came from the interaction among:

• Orange Book-listed formulation patents.
• A Paragraph IV ANDA challenge.
• The 30-month FDA approval stay.
• Settlement-based generic entry.
• Manufacturing and regulatory barriers for liquid extended-release products.

Key Takeaways

• Silvergate sued Bionpharma in Delaware over an ANDA for generic Karbinal ER.
• The product contained carbinoxamine maleate in an extended-release oral suspension.
• The dispute centered on formulation patents, principally U.S. Patent No. 8,541,450.
• Bionpharma used a Paragraph IV certification to challenge the patent position.
• The case ended through settlement and dismissal rather than a broadly reported final invalidity judgment.
• The relevant competitive pathway was generic substitution, not biosimilar competition.
• The commercial value of Silvergate’s protection depended on settlement entry terms, FDA approval, and the remaining life of the formulation patents.
• Manufacturing complexity strengthened the practical barrier beyond the patent claims alone.

Frequently Asked Questions

What was the patent number in Silvergate Pharmaceuticals v. Bionpharma?

The principal patent associated with the Karbinal ER litigation was U.S. Patent No. 8,541,450, directed to extended-release liquid pharmaceutical compositions involving carbinoxamine.

Was Bionpharma allowed to launch a generic version of Karbinal ER?

The case’s settlement and dismissal resolved the litigation, but the public docket does not establish every commercial term governing Bionpharma’s launch. Actual entry depended on the settlement, FDA approval, and applicable exclusivity periods.

Was Karbinal ER protected by a new chemical entity patent?

No. The product’s commercial patent protection focused on the extended-release formulation and delivery system rather than a new chemical entity patent for carbinoxamine.

Could a generic company avoid the Silvergate patents through a different formulation?

Potentially. A formulation patent only covers products meeting its claim limitations. A generic applicant could pursue a design-around, but the alternative product would still need to satisfy FDA quality, stability, equivalence, and labeling requirements.

Did the litigation create precedent for all oral-liquid drug patents?

No. The case resolved without a broadly reported precedential decision establishing a general rule for all oral-liquid or extended-release formulation patents.

References

1. U.S. District Court for the District of Delaware. (2017). Silvergate Pharmaceuticals, Inc. v. Bionpharma, Inc., No. 1:17-cv-00016.

2. U.S. Food and Drug Administration. (n.d.). Orange Book: Approved drug products with therapeutic equivalence evaluations. FDA.

3. U.S. Patent and Trademark Office. (2013). U.S. Patent No. 8,541,450: Extended release liquid pharmaceutical composition. USPTO.

4. U.S. Food and Drug Administration. (2024). Approved drug products and therapeutic equivalence evaluations. FDA.

5. Hatch-Waxman Amendments, 21 U.S.C. § 355(j); 35 U.S.C. § 271(e)(2).